CytoSolve® Builds Predictive Systems Architecture Linking RNAi Knockdown to Bradykinin Signaling for Hereditary Angioedema Therapeutic Optimization

Partner Description

Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a leading biopharmaceutical company pioneering RNA interference (RNAi) therapeutics. The organization focuses on translating siRNA-driven gene silencing into clinically meaningful therapies for serious diseases, including hereditary angioedema (HAE), where unmet medical need remains high.

Challenge

Hereditary angioedema (HAE) is a chronic disorder characterized by recurrent, non-pruritic swelling episodes affecting subcutaneous and submucosal tissues. Dysregulation of the contact activation system—often involving factor XII and/or C1 inhibitor (C1INH)—drives excessive bradykinin production, resulting in pathological vascular permeability.

Although siRNA therapeutics offer a promising approach to suppress key drivers of HAE biology, development was hindered by fragmented mechanistic understanding across the contact activation cascade. Specifically, limited ability to quantitatively connect gene knockdown to downstream bradykinin response complicated target prioritization, dose optimization, and rational design of combination therapies.

How CytoSolve® Helped

CytoSolve® partnered with Alnylam to construct a predictive, mechanistic systems architecture capturing HAE-relevant biology.

  • Converted contact activation and bradykinin production pathways into quantitative in silico models, enabling dynamic simulation of pathway behavior rather than isolated biomarker analysis.
  • Assessed differential sensitivity of bradykinin output to perturbations across network components, identifying nodes with the greatest influence on clinically relevant outcomes.
  • Validated model behavior against independent in vitro and in vivo literature data, ensuring biological credibility across multiple evidence sources.
  • Successfully predicted outcomes observed in Alnylam’s in vivo studies, directly linking computational simulations to experimental observations.

Key Benefits Realized

  • Mechanistic Link Between Knockdown and Response – Quantitatively connected siRNA target suppression to bradykinin-driven pathological outcomes.
  • Pathway Sensitivity Mapping – Identified leverage points within the contact activation cascade for improved target prioritization.
  • Cross-Validated Model Confidence – Grounded simulations using independent experimental evidence.
  • Predictive Preclinical Utility – Enabled forward-looking predictions aligned with in vivo findings.
  • Combination siRNA Framework – Established a rational foundation for multi-target siRNA strategy design.

Outcome

Through collaboration with CytoSolve®, Alnylam translated complex contact activation and bradykinin biology into a validated computational systems architecture capable of linking siRNA-mediated gene knockdown to downstream pathway response. Supported by literature-based validation and alignment with in vivo observations, the model provided a robust foundation for accelerating target selection and exploring rational combination siRNA strategies, strengthening therapeutic development for life-threatening hereditary angioedema.